The field of ophthalmology has witnessed a surging tide of innovations, bringing hope to countless patients worldwide. Leading this charge are pharmaceutical companies at the forefront of cutting-edge research, pushing boundaries to ensure a brighter future for eye health. In this article, I shine the spotlight on these10 pharma companies with promising pipeline assets in Phase 2 and/or Phase 3 clinical trials with potential FDA approval dates within the next three (3) years.
Here is my list of favorites:
- Opthea Limted, Melbourne, Australia. NASDAQ: OPT
Opthea is committed to improving vision in patients suffering with retinal eye diseases. Their pipeline is currently focused on Wet AMD and DME. Their lead candidate, sozinibercept (OPT-302) has two Phase 3 trials underway, SHORE & COAST with comparator arms vs Ranibizumab (Lucentis) and Aflibercept (Eylea) respectively. OPT-302 focuses on the anti-VEGF C&D pathway and will be the first adjunct to all current VEGF-A therapies on the market with the promise of improving outcomes.
During my time consulting with them, I was impressed with their management team, scientists and the promising results achieved in Phase 2A & 2B clinical trials. This company is one to watch over the next 12-18 months.
